Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 10,849 matching trials from the live ClinicalTrials.gov search.
Filters: Columbus, Ohio Clear all
Active, not recruiting Phase 3 Interventional

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

NCT05135559
View directory record Official record
Conditions
Haemophilia A and B With and Without Inhibitors
Interventions
Concizumab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
19
States / cities
San Diego, California • Aurora, Colorado • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 4, 2026, 5:13 AM EST
Completed No phase listed Observational

Work Ability in Young Adult Cancer Survivors

NCT03148080
View directory record Official record
Conditions
Cancer Survivor
Interventions
Cognitive Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years to 34 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
326
States / cities
Fairbanks, Alaska • Fort Smith, Arkansas • Anaheim, California + 221 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 2 Interventional Results available

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain

NCT04529096
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
LY3016859, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Chandler, Arizona • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Nov 4, 2026, 5:13 AM EST
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT07290062
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
INS1202
Genetic
Lead sponsor
Insmed Gene Therapy LLC
Industry
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
La Jolla, California • Palo Alto, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 4, 2026, 5:13 AM EST
Recruiting Phase 2 Interventional

Groningen International Study on Sentinel Nodes in Vulvar Cancer-III

NCT05076942
View directory record Official record
Conditions
Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases
Interventions
Radiotherapy combined with cisplatin, Cisplatin
Radiation · Drug
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years and older · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
21
States / cities
Orange, California • Miami Beach, Florida • Springfield, Massachusetts + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 3 Interventional Results available

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

NCT00520741
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
108
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 3 Interventional Results available

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

NCT05369403
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Montgomery, Alabama • Phoenix, Arizona • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 4, 2026, 5:13 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

NCT06184373
View directory record Official record
Conditions
Gestational Diabetes, Hyperglycemia
Interventions
Continuous glucose monitor, Oral Glucose Tolerance Test, Hemoglobin A1c
Device · Diagnostic Test
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 4, 2026, 5:13 AM EST
Terminated Phase 1 Interventional

Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

NCT04204941
View directory record Official record
Conditions
Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma
Interventions
Tazemetostat, Doxorubicin HCl
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Duarte, California • Santa Monica, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Nov 4, 2026, 5:13 AM EST
Completed Not applicable Interventional Results available

Proximal Protection With The Mo.Ma Device During Carotid Stenting

NCT00744523
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
Mo.Ma cerebral protection device
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Buffalo, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Nov 4, 2026, 5:13 AM EST
Completed No phase listed Observational

PA Behavior and HRQoL in Parkinson's Disease Patients Patients: Role of Social Cognitive Variables

NCT05575479
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease, Idiopathic Parkinson's Disease, Parkinson Disease, Idiopathic, Parkinson's Disease, Parkinson's Disease, Idiopathic
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 2 Interventional

Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

NCT00020696
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, tirapazamine
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
50
States / cities
Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 3 Interventional Results available

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

NCT01408303
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Disease
Interventions
Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
89
States / cities
Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Nov 4, 2026, 5:13 AM EST
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Nov 4, 2026, 5:13 AM EST
Completed Not applicable Interventional Results available

Liposomal Bupivacaine Versus Standard Analgesia in Total Joint Arthroplasty (TJA)

NCT02197273
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis, Shoulder
Interventions
Liposomal bupivacaine, Standard of care analgesia
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 2 Interventional Results available

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

NCT05869669
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Neflamapimod, Placebo
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
55 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 2 Interventional Results available

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

NCT02097641
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol

NCT00263341
View directory record Official record
Conditions
Contraception
Interventions
NES/EE CVR
Combination Product
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 3 Interventional Results available

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT00884741
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Temozolomide
Radiation · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
324
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Nov 4, 2026, 5:13 AM EST
Completed Not applicable Interventional Results available

Clinical Evaluation of Reusable Soft Contact Lenses

NCT06119191
View directory record Official record
Conditions
Myopia
Interventions
Control Lenses (comfilcon A with current process), Test Lenses (comfilcon A with novel process)
Device
Lead sponsor
CooperVision International Limited (CVIL)
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Berkeley, California • Bloomington, Indiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Nov 4, 2026, 5:13 AM EST
Not listed Phase 3 Interventional Results available

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

NCT00567580
View directory record Official record
Conditions
Prostate Cancer
Interventions
PBRT, PLNRT, AA, LHRH agonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
444
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 2 Interventional

A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002227
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Lamivudine, Stavudine
Drug
Lead sponsor
Dupont Merck
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Brookline, Massachusetts • Columbus, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 4, 2026, 5:13 AM EST
Completed Phase 4 Interventional

Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers

NCT01596920
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Tissue, Control
Other
Lead sponsor
Osiris Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Montgomery, Alabama • Glendale, Arizona • Encinitas, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Nov 4, 2026, 5:13 AM EST